Table 2.

Odds ratios^* and 95% confidence intervals for the association between endometriosis, overall and by race, for all ovarian cancer and stratified by histotype

	All histotypes	High-Grade Serous	Low-Grade Serous	Endometrioid	Clear Cell	Mucinous	pheterogeneity	Low-Grade Serous, Endo, & Clear Cell
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	between histotypes	OR (95% CI)
All participants (cases/controls)	3147/4858	1924/4858	113/4858	270/4858	212/4858	196/4858		595/4858
No	1.00	1.00	1.00	1.00	1.00	1.00		1.00
Yes	1.75 (1.45–2.11)	1.40 (1.11–1.76)	0.97 (0.41–2.30)	3.30 (2.31–4.71)	3.93 (2.64–5.83)	1.31 (0.72–2.36)	<0.001	3.05 (2.31–4.02)
Black participants (cases/controls)	951/1773	609/1773	32/1773	84/1773	35/1773	52/1773		151/1773
No	1.00	1.00	1.00	1.00	1.00	1.00		1.00
Yes	2.12 (1.50–3.00)	1.63 (1.06–2.51)	1.00 (0.13–7.99)	7.06 (3.86–12.91)	4.82 (1.81–12.85)	0.89 (0.21–3.82)	0.047	4.91 (2.93–8.23)
White participants (cases/controls)	2196/3085	1315/3085	81/3085	186/3085	177/3085	144/3085		444/3085
No	1.00	1.00	1.00	1.00	1.00	1.00		1.00
Yes	1.58 (1.26–1.98)	1.31 (1.00–1.72)	0.98 (0.38–2.55)	2.17 (1.36–3.45)	3.48 (2.24–5.41)	1.41 (0.73–2.70)	0.004	2.39 (1.71–3.34)
pheterogeneity by race	0.22	0.56	0.94	0.003	0.64	0.50

^*Odd ratios were adjusted for site, age at diagnosis, education, parity, oral contraceptive use, BMI, smoking status, tubal ligation, family history of breast or ovarian cancer, menopausal status, post-menopausal hormone duration, age at menarche, and premenopausal hysterectomy.